BioLineRx receives Notice of Allowance from USPTO for a patent

BioLineRx announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent, “Process for Manufacturing Peptide,” covering a method of manufacturing motixafortide (BL-8040) that is suitable for large scale production. In addition to a broad range of U.S. and international patents covering various aspects of motixafortide, including composition of matter, methods of synthesis, methods of use and combinations, BioLineRx was granted seven years of Orphan Drug market exclusivity beginning on September 8, 2023, the day APHEXDA was approved by the FDA, in combination with G-CSF, for use by multiple myeloma patients undergoing autologous stem cell transplantation. Additionally, motixafortide was granted five years of market exclusivity across all indications as a New Chemical Entity. The NCE exclusivity also commenced on September 8, 2023. The new patent, when issued, will be valid until December 2041.